The observed improved survival of ALM patients with concurrent MUC16 and TTN mutations might be attributed to the trend towards lower total mutation count in ALM patients with both mutations (in comparison to CM and MUP patients with both mutations), and the significantly higher total mutation count in ALM patients with neither mutations (in comparison to CM and MUP patients with neither mutations). This evidence concerns the gene TTN and acral lentiginous melanoma.